Given the critical role of BCR in the proliferation and survival of cancer cells in a variety of B-cell malignancies, disrupting BCR signaling pathways involved in tumor cell survival through targeting its components such as BTK seems to be a good therapeutic approach. Here, BCR is linked to neoplasm.